Identification

Name
Flibanserin
Accession Number
DB04908
Type
Small Molecule
Groups
Approved, Investigational
Description

Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.

Structure
Thumb
Synonyms
  • BIMT-17
  • BIMT-17-BS
External IDs
BIMT 17 / BIMT 17 BS
Product Ingredients
IngredientUNIICASInChI Key
Flibanserin hydrochloride96XTC36K1B147359-76-0XGAGFLQFMFCIHZ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AddyiTablet, film coated100 mg/1OralSprout Pharmaceuticals, Inc.2015-08-18Not applicableUs
AddyiTablet100 mgOralSprout Pharmaceuticals IncNot applicableNot applicableCanada
International/Other Brands
Ectris
Categories
UNII
37JK4STR6Z
CAS number
167933-07-5
Weight
Average: 390.4021
Monoisotopic: 390.166745929
Chemical Formula
C20H21F3N4O
InChI Key
PPRRDFIXUUSXRA-UHFFFAOYSA-N
InChI
InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
IUPAC Name
1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1

Pharmacology

Indication

For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.

TargetActionsOrganism
A5-hydroxytryptamine receptor 1A
agonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(4) dopamine receptor
antagonist
agonist
Human
Absorption

Flibanserin has an absolute oral availability of 33%.

Volume of distribution
Not Available
Protein binding

~98%, highly bound to proteins (mostly albumin) in serum.

Metabolism

Metabolism is primarily via CYP3A4, slightly CYP2C19. Minimal involvement of CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2D6. At least 35 metabolites of flibanserin are produced, 2 of which reach plasma concentrations as high as parent drug, however they are pharmacologically inactive.

Route of elimination

Elimination via feces (51%) and urine (44%) following a single oral 50 mg dose of flibanserin solution.

Half life

≈11 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Flibanserin can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Flibanserin.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Flibanserin is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flibanserin.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flibanserin.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flibanserin.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flibanserin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flibanserin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Amperozide.Experimental
AmphetamineThe metabolism of Flibanserin can be decreased when combined with Amphetamine.Approved, Illicit, Investigational
ApalutamideThe serum concentration of Flibanserin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe risk or severity of adverse effects can be increased when Aprepitant is combined with Flibanserin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Flibanserin.Approved
AtazanavirThe serum concentration of Flibanserin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Flibanserin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Azaperone.Investigational, Vet Approved
AzelastineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Flibanserin.Approved
BarbitalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Barbital.Illicit
BenmoxinThe metabolism of Flibanserin can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Flibanserin is combined with Benzyl alcohol.Approved
BoceprevirThe serum concentration of Flibanserin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Flibanserin.Approved, Investigational
BosentanThe serum concentration of Flibanserin can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
BrofaromineThe metabolism of Flibanserin can be decreased when combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Bromisoval.Experimental
BromocriptineBromocriptine may increase the vasoconstricting activities of Flibanserin.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flibanserin.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Bupivacaine.Approved, Investigational
BuprenorphineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flibanserin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flibanserin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Flibanserin.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Flibanserin is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flibanserin.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the vasoconstricting activities of Flibanserin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Flibanserin is combined with Canertinib.Investigational
CarbamazepineThe serum concentration of Flibanserin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flibanserin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Flibanserin is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flibanserin.Approved
CaroxazoneThe metabolism of Flibanserin can be decreased when combined with Caroxazone.Withdrawn
CeritinibThe serum concentration of Flibanserin can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flibanserin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe serum concentration of Flibanserin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flibanserin.Approved, Illicit, Investigational
ChlormadinoneThe serum concentration of Flibanserin can be increased when it is combined with Chlormadinone.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flibanserin.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flibanserin.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Flibanserin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Flibanserin.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Flibanserin.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Flibanserin.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Flibanserin.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flibanserin.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flibanserin.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flibanserin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Clothiapine.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Flibanserin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Flibanserin.Approved
CobicistatThe serum concentration of Flibanserin can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flibanserin.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Flibanserin.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Crizotinib is combined with Flibanserin.Approved
CurcuminThe serum concentration of Flibanserin can be increased when it is combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flibanserin.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flibanserin.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flibanserin.Approved
Cyproterone acetateThe serum concentration of Flibanserin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Flibanserin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Flibanserin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Flibanserin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe risk or severity of adverse effects can be increased when Delavirdine is combined with Flibanserin.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Flibanserin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Flibanserin.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flibanserin.Approved, Investigational
DesogestrelThe serum concentration of Flibanserin can be increased when it is combined with Desogestrel.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flibanserin.Approved, Illicit, Investigational, Vet Approved
DienogestThe serum concentration of Flibanserin can be increased when it is combined with Dienogest.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Flibanserin is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Flibanserin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Flibanserin.Approved, Illicit
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flibanserin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flibanserin.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flibanserin.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Flibanserin.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flibanserin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flibanserin.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flibanserin.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flibanserin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Flibanserin.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Flibanserin is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Illicit
DronedaroneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Flibanserin.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Vet Approved
DrospirenoneThe serum concentration of Flibanserin can be increased when it is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Drotebanol.Experimental, Illicit
DroxidopaFlibanserin may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Flibanserin.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Flibanserin.Approved, Investigational
EnzalutamideThe serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Flibanserin.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Flibanserin.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Flibanserin.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Flibanserin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flibanserin.Approved, Illicit
EstradiolThe serum concentration of Flibanserin can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Flibanserin can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Flibanserin can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flibanserin.Approved, Investigational
EthanolEthanol may increase the hypotensive activities of Flibanserin.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Flibanserin can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flibanserin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Flibanserin can be increased when it is combined with Ethynodiol diacetate.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etomidate.Approved
EtonogestrelThe serum concentration of Flibanserin can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Flibanserin.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flibanserin.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluanisone.Experimental
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Flibanserin.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Flibanserin.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flibanserin.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flibanserin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flibanserin.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flibanserin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Flibanserin.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Flibanserin.Approved
FosaprepitantThe serum concentration of Flibanserin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Flibanserin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe metabolism of Flibanserin can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Flibanserin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flibanserin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Flibanserin is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Flibanserin.Approved, Illicit, Investigational
GemfibrozilThe serum concentration of Flibanserin can be increased when it is combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Flibanserin is combined with Gepirone.Investigational
GestodeneThe serum concentration of Flibanserin can be increased when it is combined with Gestodene.Approved, Investigational
GestrinoneThe serum concentration of Flibanserin can be increased when it is combined with Gestrinone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Halothane.Approved, Vet Approved
HarmalineThe metabolism of Flibanserin can be decreased when combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Hexobarbital.Approved
HydracarbazineThe metabolism of Flibanserin can be decreased when combined with Hydracarbazine.Experimental
HydrocodoneFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Flibanserin can be increased when it is combined with Hydroxyprogesterone caproate.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
IdelalisibThe serum concentration of Flibanserin can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Iloperidone.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Flibanserin.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Flibanserin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Flibanserin can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Flibanserin is combined with Indiplon.Investigational
IproclozideThe metabolism of Flibanserin can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Flibanserin can be decreased when combined with Iproniazid.Withdrawn
IsavuconazoleThe risk or severity of adverse effects can be increased when Isavuconazole is combined with Flibanserin.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Isavuconazonium is combined with Flibanserin.Approved, Investigational
IsocarboxazidThe metabolism of Flibanserin can be decreased when combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flibanserin.Approved, Vet Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Flibanserin.Approved, Investigational
ItraconazoleThe serum concentration of Flibanserin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Flibanserin can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flibanserin.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Flibanserin can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flibanserin.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flibanserin.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Flibanserin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe serum concentration of Flibanserin can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flibanserin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lidocaine.Approved, Vet Approved
Lithium cationThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Flibanserin can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Flibanserin can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Flibanserin.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flibanserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Flibanserin can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Flibanserin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flibanserin.Approved
LuliconazoleThe risk or severity of adverse effects can be increased when Luliconazole is combined with Flibanserin.Approved
LumacaftorThe serum concentration of Flibanserin can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flibanserin.Approved, Investigational
LynestrenolThe serum concentration of Flibanserin can be increased when it is combined with Lynestrenol.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Flibanserin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.Approved, Investigational
MebanazineThe metabolism of Flibanserin can be decreased when combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Flibanserin is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Flibanserin.Approved
MedazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Flibanserin can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe serum concentration of Flibanserin can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Flibanserin is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Mesoridazine.Approved, Investigational
MestranolThe serum concentration of Flibanserin can be increased when it is combined with Mestranol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Flibanserin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flibanserin.Approved
MethotrimeprazineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methylecgonine.Experimental
Methylene blueThe metabolism of Flibanserin can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the vasoconstricting activities of Flibanserin.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methylphenobarbital.Approved
MetyrosineFlibanserin may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.Approved, Illicit
MifepristoneThe risk or severity of adverse effects can be increased when Mifepristone is combined with Flibanserin.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Flibanserin is combined with Milnacipran.Approved, Investigational
MinaprineThe metabolism of Flibanserin can be decreased when combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Investigational
MirtazapineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Flibanserin can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Flibanserin can be decreased when combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flibanserin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flibanserin.Approved
NefazodoneThe serum concentration of Flibanserin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Flibanserin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe risk or severity of adverse effects can be increased when Netupitant is combined with Flibanserin.Approved, Investigational
NevirapineThe risk or severity of adverse effects can be increased when Nevirapine is combined with Flibanserin.Approved
NialamideThe metabolism of Flibanserin can be decreased when combined with Nialamide.Withdrawn
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Flibanserin.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flibanserin.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Flibanserin.Approved, Vet Approved
Nomegestrol acetateThe serum concentration of Flibanserin can be increased when it is combined with Nomegestrol acetate.Approved, Investigational
NordazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Nordazepam.Approved
NorelgestrominThe serum concentration of Flibanserin can be increased when it is combined with Norelgestromin.Approved, Investigational
NorethisteroneThe serum concentration of Flibanserin can be increased when it is combined with Norethisterone.Approved
NorethynodrelThe serum concentration of Flibanserin can be increased when it is combined with Norethynodrel.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Norflurane.Approved, Investigational
NorgestimateThe serum concentration of Flibanserin can be increased when it is combined with Norgestimate.Approved, Investigational
NorgestrelThe serum concentration of Flibanserin can be increased when it is combined with Norgestrel.Approved
NorgestrienoneThe serum concentration of Flibanserin can be increased when it is combined with Norgestrienone.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flibanserin.Approved
OctamoxinThe metabolism of Flibanserin can be decreased when combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flibanserin.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Flibanserin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flibanserin.Approved
OndansetronThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Flibanserin is combined with Opium.Approved, Illicit
OrphenadrineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Flibanserin is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Flibanserin can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flibanserin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Flibanserin is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flibanserin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flibanserin.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Flibanserin can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flibanserin.Approved
ParaldehydeFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe metabolism of Flibanserin can be decreased when combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.Approved, Vet Approved
PentobarbitalThe serum concentration of Flibanserin can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
PerazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Flibanserin is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flibanserin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flibanserin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenazocine.Experimental
PhenelzineThe metabolism of Flibanserin can be decreased when combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenibut.Experimental
PheniprazineThe metabolism of Flibanserin can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe serum concentration of Flibanserin can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenoxyethanol.Approved
PhenoxypropazineThe metabolism of Flibanserin can be decreased when combined with Phenoxypropazine.Withdrawn
PhenytoinThe serum concentration of Flibanserin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Flibanserin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flibanserin.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Piritramide.Approved, Investigational
PirlindoleThe metabolism of Flibanserin can be decreased when combined with Pirlindole.Approved
PitolisantThe serum concentration of Flibanserin can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe metabolism of Flibanserin can be decreased when combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Flibanserin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleFlibanserin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Flibanserin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Prilocaine.Approved
PrimidoneThe serum concentration of Flibanserin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe metabolism of Flibanserin can be decreased when combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe metabolism of Flibanserin can be decreased when combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flibanserin.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Flibanserin is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Flibanserin.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Flibanserin is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Flibanserin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.Approved
QuingestanolThe serum concentration of Flibanserin can be increased when it is combined with Quingestanol.Experimental
QuinisocaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flibanserin.Approved, Investigational
RanolazineThe risk or severity of adverse effects can be increased when Ranolazine is combined with Flibanserin.Approved, Investigational
RasagilineThe metabolism of Flibanserin can be decreased when combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flibanserin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flibanserin.Approved, Investigational
RifabutinThe serum concentration of Flibanserin can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Flibanserin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Flibanserin can be decreased when it is combined with Rifapentine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Romifidine.Vet Approved
RopiniroleFlibanserin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ropivacaine.Approved
RotigotineFlibanserin may increase the sedative activities of Rotigotine.Approved
RucaparibThe risk or severity of adverse effects can be increased when Rucaparib is combined with Flibanserin.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flibanserin.Approved
SafrazineThe metabolism of Flibanserin can be decreased when combined with Safrazine.Withdrawn
SaquinavirThe serum concentration of Flibanserin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Flibanserin can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flibanserin.Approved, Vet Approved
SelegilineThe metabolism of Flibanserin can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flibanserin.Approved, Vet Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Flibanserin.Approved, Investigational
SiltuximabThe serum concentration of Flibanserin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Flibanserin.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
St. John's WortThe serum concentration of Flibanserin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Flibanserin can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.Approved, Investigational
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Flibanserin.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sultopride.Experimental
SuvorexantFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tasimelteon.Approved, Investigational
TelaprevirThe serum concentration of Flibanserin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Flibanserin can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flibanserin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flibanserin.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tetrodotoxin.Investigational
ThalidomideFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Flibanserin is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flibanserin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flibanserin.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tiapride.Approved, Investigational
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Flibanserin.Approved
TiletamineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.Approved, Investigational
TocilizumabThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flibanserin.Approved, Withdrawn
ToloxatoneThe metabolism of Flibanserin can be decreased when combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Flibanserin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flibanserin.Approved, Investigational
TranylcypromineThe metabolism of Flibanserin can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flibanserin.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flibanserin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flibanserin.Approved
UlipristalThe serum concentration of Flibanserin can be increased when it is combined with Ulipristal.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Flibanserin is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Flibanserin can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Flibanserin.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Flibanserin.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Flibanserin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Flibanserin can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Flibanserin is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flibanserin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Flibanserin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zolazepam.Vet Approved
ZolpidemFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flibanserin.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Flibanserin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707]
  2. Scandroglio A, Monferini E, Borsini F: Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors. Pharmacol Res. 2001 Feb;43(2):179-83. [PubMed:11243720]
  3. Borsini F, Cesana R: Mechanism of action of flibanserin in the learned helplessness paradigm in rats. Eur J Pharmacol. 2001 Dec 14;433(1):81-9. [PubMed:11755137]
  4. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684]
  5. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054]
  6. Stahl SM: Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015 Feb;20(1):1-6. doi: 10.1017/S1092852914000832. Epub 2015 Feb 9. [PubMed:25659981]
External Links
KEGG Drug
D02577
PubChem Compound
6918248
PubChem Substance
175426897
ChemSpider
5293454
ChEBI
90865
ChEMBL
CHEMBL231068
PharmGKB
PA166153431
Drugs.com
Drugs.com Drug Page
Wikipedia
Flibanserin
ATC Codes
G02CX02 — Flibanserin
AHFS Codes
  • 28:92.00 — Miscellaneous Central Nervous System Agents
FDA label
Download (788 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSexual Dysfunctions, Psychological1
3CompletedTreatmentSexual Dysfunctions, Psychological7
3TerminatedTreatmentSexual Dysfunctions, Psychological3
4RecruitingTreatmentHypoactive Sexual Desire Disorder (HSDD)1
Not AvailableRecruitingBasic ScienceHypoactive Sexual Desire Disorder (HSDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral100 mg
Tablet, film coatedOral100 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7151103No2003-05-092023-05-09Us
US8227471No2003-05-092023-05-09Us
US7420057No2002-08-012022-08-01Us
US9468639No2002-10-162022-10-16Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.178 mg/mLALOGPS
logP3.32ALOGPS
logP3.83ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)12.91ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.82 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity103.65 m3·mol-1ChemAxon
Polarizability38.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9857
Caco-2 permeable-0.7652
P-glycoprotein substrateSubstrate0.6865
P-glycoprotein inhibitor IInhibitor0.8895
P-glycoprotein inhibitor IIInhibitor0.8741
Renal organic cation transporterInhibitor0.6378
CYP450 2C9 substrateNon-substrate0.7906
CYP450 2D6 substrateNon-substrate0.5905
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.8379
CYP450 2C9 inhibitorNon-inhibitor0.7028
CYP450 2D6 inhibitorInhibitor0.5876
CYP450 2C19 inhibitorNon-inhibitor0.59
CYP450 3A4 inhibitorInhibitor0.7523
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9005
Ames testNon AMES toxic0.6798
CarcinogenicityNon-carcinogens0.9354
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6546 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6138
hERG inhibition (predictor II)Inhibitor0.9486
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Trifluoromethylbenzenes / Benzimidazoles / Aniline and substituted anilines / Dialkylarylamines / N-alkylpiperazines / N-substituted imidazoles / Heteroaromatic compounds / Trialkylamines / Ureas
show 7 more
Substituents
Phenylpiperazine / N-arylpiperazine / Trifluoromethylbenzene / Benzimidazole / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / N-alkylpiperazine / Monocyclic benzene moiety / N-substituted imidazole
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707]
  2. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684]
  2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684]
  2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054]

Drug created on October 21, 2007 16:23 / Updated on July 13, 2018 01:09